The collection of Chinese patent medicines is here!

Recently, Hubei led the 19-province alliance to open bids for the centralized procurement of proprietary Chinese medicines
.
This is the first centralized procurement of Chinese patent medicine alliance in the country
.
According to the calculation of the annual demand of the 19-province alliance, it is expected to save more than 2.
6 billion yuan in drug costs each year
.
Why is Chinese patent medicine the "hard bone" of centralized collection? Over the years, the problem of inflated prices has not only existed in the chemical, biological and consumable industries, but also in the Chinese patent medicine industry, and the people have expressed strong reactions
.
However, since the reform of centralized drug procurement in 2018, no Chinese patent medicine has been included in large-scale centralized procurement
.
This is because Chinese patent medicines have their particularities, and it is quite difficult to carry out centralized procurement
.
First, the quality of Chinese patent medicines is difficult to evaluate, and secondly, there are many exclusive products of Chinese patent medicines
.
The person in charge of the Department of Medicine Price and Bidding and Purchasing of the National Medical Insurance Bureau said that in recent years, the state has strongly supported the development of traditional Chinese medicine.
Unreasonable recognition of inflated drug prices that increase the burden on the masses; the particularity of the industry is not a safe haven for inflated drug prices
.
The person in charge said that it is one of the important meanings of centralized procurement to solve problems such as decoupling of volume and price in the drug purchase and sales chain, non-standard competition, and gold sales through volume-based procurement.
It is also the alliance of 19 provinces to conduct proprietary Chinese medicine One of the reasons for centralized procurement: not only to let the people enjoy lower drug prices, but also to purify the industry environment, so that drugs can return to the essential attributes of curing diseases and saving people
.
Therefore, no matter how difficult it is, the medical insurance department has to bite the hard bone
.
It is expected to save more than 2.
6 billion yuan in drug costs each year.
The reporter learned from the National Medical Insurance Bureau that in this centralized procurement, 182 products from 157 companies participated in the quotation, with a procurement scale of nearly 10 billion yuan; in the end, 97 companies, 111 products The products were selected, the selection rate reached 62%, the average price of the selected products decreased by 42.
27%, and the largest decrease was 82.
63%
.
According to the calculation of the annual demand of the 19-province alliance, it is expected to save more than 2.
6 billion yuan in drug costs each year.

.
The person in charge of the Department of Medicine Price and Bidding and Purchasing of the National Medical Insurance Administration said that the problem of price differences between the same medicines has a long history and the causes are complicated
.
High prices are due to factors such as quality level and brand premium, as well as inflated space and weak cost control capabilities; low prices may reflect factors such as strong cost control capabilities and market strategies, or may be due to low brand recognition and curative effect.
There are factors such as insufficient recognition, and there are problems such as too low prices and no supply
.
The purpose of centralized procurement of proprietary Chinese medicines is not to level the price, nor to level the cost and profit of the production enterprise, but to remove or reduce the unreasonably high part between the actual ex-factory price and the terminal selling price of the enterprise, and to improve the unreasonable The sales model allows the selected products to obtain no less than the original market and more sales without excessive marketing.
It is a collective process of eliminating "puffiness"
.
According to reports, in this centralized procurement, the selected price was quoted by the enterprise in combination with factors such as quality, efficacy, supply, and credit.
Responded to the reasonable demands of the industry
.
In the next step, all localities will further improve the procurement rules on the basis of continuous summarization, and strive to achieve a balance of more diverse goals
.
Jiang Changsong, director of the Price Recruitment and Procurement Office of the National Medical Security Research Institute, said that the results of the selected price for this centralized procurement with volume met expectations, generally in line with the principle of linking volume and price, and most products, especially those with large procurement volume, have reached the expected price.
quite a drop
.
In the subsequent process of checking the balance and purchasing and using, the medical insurance department will further guide medical institutions and medical personnel to give priority to the selected products with good quality and reasonable price
.
Of course, it is also necessary to further summarize the experience in the centralized procurement of proprietary Chinese medicines, improve the rules, and guide enterprises to compete better
.
(Finish)